Staying Ahead of the Game
Nothing says “end of summer” like high school football practice, apple cider, and Halloween decorations. Everyone packs up their sand chairs and boogie boards and heads back to the classroom, or workplace, whichever is most applicable. Here at MJH Life Sciences®, where education and events go hand-in-hand, our studios have been polished up all summer to bring a series of medical education programs for our physician audience. Titles such as NSCLC Insights, CKD Stakeholder Summit, and Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME, are all intended to help physicians improve their patients’ outcomes.
On the Industry Sciences side, MJH strives to contribute to these efforts in a different way. We inform and educate those professionals who research new compounds, investigate potential therapies in clinical trials, manufacture and distribute these drugs, and who also inform patients and healthcare professionals (HCPs) on the most appropriate ways to take advantage of
innovative drugs.
Here, in addition to events, Industry Sciences offers webcasts, digitally-enhanced “books” and magazines, videos, podcasts, and other forms of educational material for our audiences.
Some current topics that may have relevance to clinical trial professionals when peeking ahead to potential commercial viability, especially those developing hopeful advanced and curative treatments, include:
The American Medical Association reports that overall health spending was 18.3% of GDP in 2021 compared with 19.7% of GDP in 2020. That figure was down a bit, but still represents a hefty piece of the pie. Of this, 31.1% went to hospital care, 14.9% to physician services, and 8.9% to prescription drugs.
Of course with any large enterprise, complexities abound. This complexity—a constantly evolving and moving target—ensures that learning new information must take precedence for all decision-makers. Please take advantage of our many resources as you head back to work and educate yourself on all the latest issues, challenges, and strategic guidance impacting your decisions.
Thank you for reading.
Mike Hennessy Jr. is the president and CEO of Applied Clinical Trials' parent company, MJH Life Sciences®
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
